Welcome to our dedicated page for Arbutus Biopharma Corporation news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharma Corporation stock.
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection (cHBV). Utilizing its extensive expertise in virology, Arbutus focuses on developing a portfolio of drug candidates with multiple mechanisms of action aimed at curing Hepatitis B virus (HBV) disease. The company's lead RNA interference (RNAi) therapeutic, imdusiran (AB-729), targets HBV proteins to reduce viral antigens and reawaken the host's immune response. Imdusiran is currently undergoing multiple Phase 2a clinical trials, demonstrating promising results in reducing hepatitis B surface antigen (HBsAg) levels and achieving functional cures in a subset of patients.
Arbutus leverages its proprietary lipid nanoparticle (LNP) technology and expertise in RNAi therapeutics to develop innovative treatments. Beyond HBV, the company has a robust pipeline that includes AB-101, an oral PD-L1 inhibitor, currently in Phase 1a/1b trials. This compound aims to enable controlled checkpoint blockade while minimizing systemic safety issues.
Recent clinical data highlight the potential of Arbutus' combination therapies. In the IM-PROVE I trial, imdusiran combined with pegylated interferon alfa-2a (IFN) and nucleos(t)ide analogue (NA) therapy demonstrated sustained HBsAg loss in some patients, suggesting a path toward a functional cure. Another study, IM-PROVE II, showed that combining imdusiran with VTP-300, an immunotherapeutic, resulted in meaningful reductions in HBsAg levels and the discontinuation of NA therapy in a significant number of patients.
Financially, Arbutus maintains a strong position with a cash runway extending into the first quarter of 2026. They are actively involved in ongoing patent litigation to protect their LNP technology, seeking fair compensation for its use in mRNA COVID-19 vaccines by Moderna and Pfizer/BioNTech.
Arbutus continues to engage in strategic collaborations and partnerships to advance its mission of curing HBV and other chronic infectious diseases. For more detailed information, visit www.arbutusbio.com.
Arbutus Biopharma Corporation (Nasdaq: ABUS) and Vaccitech plc (Nasdaq: VACC) announced the dosing of the first patient in a Phase 2a clinical trial evaluating the RNAi therapeutic AB-729 in combination with VTP-300 and nucleos(t)ide reverse transcriptase inhibitor therapy, targeting chronic HBV infection. The trial will enroll 40 patients to assess safety and antiviral activity. AB-729 aims to reduce HBV viral proteins, potentially reawakening the immune system. This collaboration seeks to improve HBsAg reduction and T-cell responses.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in two upcoming investor conferences in New York. The Jefferies Healthcare Conference will take place from June 8-10, 2022, featuring a fireside chat with key executives on June 9 at 3:00 pm ET. The JMP Securities Life Sciences Conference is scheduled for June 15-16, 2022, with a fireside chat on June 15 at 9:00 am ET. Live webcasts can be accessed via the company's website. Arbutus specializes in developing therapeutics for viral diseases, including Hepatitis B and coronaviruses.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that its abstract on a preclinical oncology study of an oral PD-L1 inhibitor will be published at the ASCO Annual Meeting on June 3-7, 2022. The abstract titled "Pre-clinical anti-tumor activity of small-molecule oral PD-L1 checkpoint inhibitors" focuses on the compound's potential to stimulate the immune system. This publication may enhance Arbutus' visibility in oncology, complementing its efforts in viral diseases like Hepatitis B and SARS-CoV-2.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that its President and CEO, William Collier, will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 11:30 am ET in Miami, FL. The conference will focus on Arbutus' innovative therapeutics targeting viral diseases, especially its lead compound AB-729, aimed at treating chronic Hepatitis B. A live webcast can be accessed via Arbutus' website, with an archived replay available afterward.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported first quarter 2022 financial results, highlighting significant advancements in its chronic hepatitis B virus (cHBV) and pan-coronavirus programs. The company achieved revenue of $12.6 million, a substantial increase from $2.1 million in Q1 2021, primarily due to a $9.6 million license agreement with Qilu Pharmaceutical. Although the net loss decreased to $15.8 million from $19.6 million year-over-year, research and development expenses rose to $18.5 million. Arbutus maintains a cash runway projected into the second quarter of 2024.
Arbutus Biopharma (Nasdaq: ABUS) will release its first quarter 2022 financial results on May 5, 2022, at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. Investors can access the conference call via the company's website or through specific dial-in numbers provided. The company focuses on developing novel therapeutics targeting viral diseases, including Hepatitis B and coronaviruses, with ongoing phase 2 clinical trials for its lead compound, AB-729, aimed at providing a functional cure for HBV.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported its Q4 and year-end 2021 results, highlighting a net loss of $88.4 million, or $0.83 per share. The company has $191 million in cash and investments, compared to $123 million in 2020. Notably, it anticipates key clinical trial data for its HBV therapies later this year. Arbutus plans to advance several compounds, including AB-101 and AB-161, into IND-enabling studies and filed a patent infringement lawsuit against Moderna regarding its COVID-19 vaccine. The company expects a cash burn of $90-$95 million in 2022.
Arbutus Biopharma Corporation (Nasdaq: ABUS) and Genevant Sciences have filed a lawsuit against Moderna (Nasdaq: MRNA) for patent infringement regarding their mRNA COVID-19 vaccine, MRNA-1273. The patents in question cover nucleic acid-lipid particles and related technologies. Arbutus CEO, William Collier, emphasized they are not seeking to halt vaccine sales but are pursuing compensation for their patented technology, crucial for vaccine success. Additionally, a previous court ruling upheld the validity of the patents involved, posing potential ongoing challenges for Moderna.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced it will release its fourth quarter and year-end 2021 financial results on March 3, 2022, at 7:30 a.m. ET, followed by a conference call at 8:45 a.m. ET. The company focuses on developing therapeutics for viral diseases, including ongoing clinical trials for its lead compound, AB-729, targeting Hepatitis B virus. A live webcast will be available on Arbutus' investor website, and an archived version will be accessible after the event.
Arbutus Biopharma Corporation (NASDAQ: ABUS) announced its 2022 objectives and financial status, highlighting anticipated clinical data readouts for its HBV candidates AB-729 and AB-836. The company completed IND-enabling studies for oral therapies AB-101 and AB-161. Significant cash reserves amounting to $191 million provide a runway into Q2 2024. CEO William Collier emphasized the importance of this year for HBV research, with multiple clinical trials underway and results expected to further support Phase 2b development.
FAQ
What is the current stock price of Arbutus Biopharma Corporation (ABUS)?
What is the market cap of Arbutus Biopharma Corporation (ABUS)?
What is Arbutus Biopharma's primary focus?
What is imdusiran (AB-729)?
What are the key recent achievements of Arbutus Biopharma?
What is the status of Arbutus' financial condition?
What technologies does Arbutus leverage for its treatments?
What are the current projects Arbutus Biopharma is working on?
Has Arbutus formed any strategic partnerships?
What is the significance of Arbutus' patent litigation?
How successful have Arbutus' clinical trials been?
Where can more information about Arbutus Biopharma be found?
